Search reports.
Chronic Ocular Surface Pain Market Size, Share & Trends 2032
Get free sample report Request for Customiztion Buy Now

Chronic Ocular Surface Pain Market Size, Share & Trends 2032

Segments - Chronic Ocular Surface Pain Market by Drug Class (Corticosteroids, Antibiotics, Nonsteroidal Anti-inflammatory (NSAID), and Others), Application (Sinusitis, Migraines, Glaucoma, and Others), End-user (Hospitals, Homecare, Specialty Clinics, and Others), and Distribution Channel (Online Pharmacy, Hospitals Pharmacy, Retail Pharmacy, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2024–2032

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-6587 | 4.9 Rating | 47 Reviews | 248 Pages | Format : PDF Excel PPT

Report Description


Chronic Ocular Surface Pain Market Outlook 2032

The global chronic ocular surface pain market size was USD 198.5 Million in 2023 and is projected to reach USD 270.54 Million by 2032, expanding at a CAGR of 3.5% during 2024–2032. The market growth is attributed to the high prevalence of lifestyle-related ocular.

Growing geriatric population is resulting in high utilization of chronic ocular surface pain treatment for their various eye condition, thereby boosting the market. The increasing life expectancy globally is contributing to a high number of elderly individuals requiring ocular care. This demographic shift and massive patient pool underscores the need for specialized treatments and long-term pain management solutions. Furthermore, the rising awareness and education campaigns about ocular health and chronic ocular surface pain further boosts the market.

  • According to the report published by the WHO, the global population of individuals aged 60 and above is projected to reach 2.1 billion by the year 2050.

Chronic Ocular Surface Pain Market Outlook

Impact of Artificial Intelligence (AI) in Chronic Ocular Surface Pain Market

The use of artificial intelligence is likely to boost the Chronic Ocular Surface Pain market. AI-driven telemedicine platforms facilitate remote consultations, enhancing accessibility to specialized care for patients in underserved regions. Additionally, AI-enabled robotic surgical systems assist ophthalmic surgeons in performing intricate procedures with unprecedented precision, minimizing the risk of complications and accelerating patient recovery times.

Chronic Ocular Surface Pain Market Dynamics

Chronic Ocular Surface Pain Market Dynamics

Major Drivers

Increasing prevalence of chronic ocular conditions is anticipated to drive the market during the forecast period. Conditions, such as dry eye disease, blepharitis, and meibomian gland dysfunction are becoming common due to factors, including aging populations and higher screen time. This rise in chronic ocular conditions leads to a higher demand for effective pain management therapies. Furthermore, the growing awareness about managing chronic ocular pain intensifies further boosts the market.

  • According to the report published by the National Library of Medicine on January 11, 2023, dry Eye Disease (DED) stands out as one of the most widespread eye conditions, impacting millions of individuals worldwide. Its prevalence varies globally, ranging from 5% to 50%, contingent upon the geographic region.

Existing Restraints

High cost of treatment is expected to hamper the market during the forecast period. Specialized treatments, advanced diagnostic tools, and long-term management strategies are often expenses. Furthermore, the limited awareness about chronic ocular surface pain and its management further hinders the market.

Emerging Opportunities

Surging advancements in medical technology are expected to create immense opportunities for the players competing in the market. Manufacturing is focusing on innovations, such as improved diagnostic devices, minimally invasive procedures, and novel therapeutic approaches to enhance the effectiveness and accessibility of treatment. These technological advancements enable accurate diagnosis, better monitoring of disease progression, and effective pain relief options. Furthermore, the high demand for innovative chronic ocular surface pain treatments further propels the market.

Scope of the Chronic Ocular Surface Pain Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Attributes

Details

Report Title

Chronic Ocular Surface Pain Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2023

Historic Data

2017 -2022

Forecast Period

2024–2032

Segmentation

Drug Class (Corticosteroids, Antibiotics, Nonsteroidal Anti-inflammatory (NSAID), and Others), Application (Sinusitis, Migraines, Glaucoma, and Others), End-user (Hospitals, Homecare, Specialty Clinics, and Others), and Distribution Channel (Online Pharmacy, Hospitals Pharmacy, Retail Pharmacy, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast

Key Players Covered in the Report

AstraZeneca; F. Hoffmann-La Roche Ltd; GSK plc; Johnson & Johnson Services, Inc; Merck KGaA; Novartis AG; OKYO Pharma; Pfizer Inc; Sanofi; Sun Pharmaceutical Industries Ltd; and Viatris Inc


Regional Outlook

In terms of region, the global chronic ocular surface pain market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023, due to the region’s robust research and development activities and the presence of leading pharmaceutical companies to support the availability and adoption of innovative treatments. Additionally, increased awareness and proactive healthcare practices contributed to early diagnosis and effective management of ocular pain, thereby boosting the market.

The market in Asia Pacific is projected to grow at a significant pace in the years to come, owing to the rising demand for chronic ocular surface pain treatments. The presence of a large and aging population, particularly in countries, including China and India creates demand for chronic ocular surface pain treatments. Furthermore, the expanding healthcare access, and government initiatives to enhance healthcare services further propel the market in this region.

Chronic Ocular Surface Pain Market Region

Chronic Ocular Surface Pain Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the chronic ocular surface pain market is divided into corticosteroids, antibiotics, nonsteroidal anti-inflammatory (NSAID), and others. The antibiotics segment is expected to expand at a significant growth rate in the coming years, due to the development of targeted therapies with improved efficacy and safety profiles.

Antibiotics, which include monoclonal antibodies and other complex molecules, help manage severe cases of chronic ocular pain that do not respond well to traditional treatments. Furthermore, increasing investment in research and clinical trials for biologics their potential to provide long-term relief and fewer side effects, is likely to propel their adoption in the coming years.

Chronic Ocular Surface Pain Market Drug Class

Application Segment Analysis

On the basis of application, the global market is segregated into sinusitis, migraines, glaucoma, and others. The glaucoma segment is anticipated to grow at a substantial CAGR during the forecast period, due to the high prevalence of glaucoma impacting the disease on patients' quality of life.

Glaucoma management often involves long-term treatment plans to control intraocular pressure and alleviate associated pain. The chronic nature of the condition and the need for continuous care creating demand for effective pain management solutions. Furthermore, the growing number of adults suffering with glaucoma further boosts the market during the forecast period.

  • As per the report published by the Glaucoma Research Foundation on March 23, 2022, there are an estimated 80 million individuals worldwide living with glaucoma.

End-user Segment Analysis

Based on end-user, the chronic ocular surface pain market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment led the market in terms of revenue in 2023, as they offer specialized care focused on specific eye conditions and personalized patient management. Furthermore, the growing preference for specialized care and the expertise available in these hospitals further attract patients seeking effective management of chronic ocular surface pain. These all factors are contributing to boosting the segment in the coming years.

The specialty clinics segment is projected to register a robust growth rate during the assessment years, owing to their direct access to patients receiving treatment. These clinics ensure timely availability of prescribed medications and offer professional guidance on drug usage and management. Moreover, their integration within the hospital ecosystem facilitates comprehensive care, making them a preferred choice for patients and further fuels the segment.

Chronic Ocular Surface Pain Market End User

Distribution Channel Segment Analysis

On the basis of distribution channel, the market is divided into online pharmacy, hospitals pharmacy, retail pharmacy, and others. The online pharmacies segment is expected to lead the market in terms of revenue during the projection period, owing to the increasing adoption of e-commerce and digital health solutions.

Convenience, competitive pricing, and a broad range of available products make online pharmacies an attractive option for patients managing chronic conditions. Furthermore, the growing trend of digital health and the expansion of online healthcare services further propels the segment during the forecast period.

Segments

The Chronic Ocular Surface Pain market has been segmented on the basis of

Drug Class

  • Corticosteroids
  • Antibiotics
  • Nonsteroidal Anti-inflammatory
  • NSAID
  • Others

Application

  • Sinusitis
  • Migraines
  • Glaucoma
  • Others

End-user

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Online Pharmacy
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Others

Region

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

Competitive Landscape

Key players competing in the global Chronic Ocular Surface Pain market are AstraZeneca; F. Hoffmann-La Roche Ltd; GSK plc; Johnson & Johnson Services, Inc; Merck KGaA; Novartis AG; OKYO Pharma; Pfizer Inc; Sanofi; Sun Pharmaceutical Industries Ltd; and Viatris Inc

These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide. For instance,

  • On February 9, 2024, OKYO Pharma, Limited, announced FDA approval for OK-101 in treating Neuropathic Corneal Pain (NCP). This drug is tailored to address the unmet medical need for NCP sufferers. Additionally, OK-101 is poised to undergo placebo-controlled, randomized, double-masked Phase 2 clinical trials, with trials anticipated to commence in the second quarter of 2024.

    Chronic Ocular Surface Pain Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Chronic Ocular Surface Pain Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Chronic Ocular Surface Pain Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Chronic Ocular Surface Pain Market - Supply Chain
  4.5. Global Chronic Ocular Surface Pain Market Forecast
     4.5.1. Chronic Ocular Surface Pain Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Chronic Ocular Surface Pain Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Chronic Ocular Surface Pain Market Absolute $ Opportunity
5. Global Chronic Ocular Surface Pain Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Chronic Ocular Surface Pain Market Size and Volume Forecast by Applications
     5.3.1. Sinusitis
     5.3.2. Migraines
     5.3.3. Glaucoma
     5.3.4. Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Chronic Ocular Surface Pain Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Chronic Ocular Surface Pain Market Size and Volume Forecast by End Users
     6.3.1. Hospitals
     6.3.2. Homecare
     6.3.3. Specialty Clinics
     6.3.4. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Chronic Ocular Surface Pain Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Chronic Ocular Surface Pain Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Chronic Ocular Surface Pain Demand Share Forecast, 2019-2026
8. North America Chronic Ocular Surface Pain Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Chronic Ocular Surface Pain Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Chronic Ocular Surface Pain Market Size and Volume Forecast by Applications
     8.4.1. Sinusitis
     8.4.2. Migraines
     8.4.3. Glaucoma
     8.4.4. Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. North America Chronic Ocular Surface Pain Market Size and Volume Forecast by End Users
     8.7.1. Hospitals
     8.7.2. Homecare
     8.7.3. Specialty Clinics
     8.7.4. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Chronic Ocular Surface Pain Demand Share Forecast, 2019-2026
9. Latin America Chronic Ocular Surface Pain Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Chronic Ocular Surface Pain Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Chronic Ocular Surface Pain Market Size and Volume Forecast by Applications
     9.4.1. Sinusitis
     9.4.2. Migraines
     9.4.3. Glaucoma
     9.4.4. Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Latin America Chronic Ocular Surface Pain Market Size and Volume Forecast by End Users
     9.7.1. Hospitals
     9.7.2. Homecare
     9.7.3. Specialty Clinics
     9.7.4. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Chronic Ocular Surface Pain Demand Share Forecast, 2019-2026
10. Europe Chronic Ocular Surface Pain Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Chronic Ocular Surface Pain Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Chronic Ocular Surface Pain Market Size and Volume Forecast by Applications
     10.4.1. Sinusitis
     10.4.2. Migraines
     10.4.3. Glaucoma
     10.4.4. Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Europe Chronic Ocular Surface Pain Market Size and Volume Forecast by End Users
     10.7.1. Hospitals
     10.7.2. Homecare
     10.7.3. Specialty Clinics
     10.7.4. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Chronic Ocular Surface Pain Demand Share Forecast, 2019-2026
11. Asia Pacific Chronic Ocular Surface Pain Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Chronic Ocular Surface Pain Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Chronic Ocular Surface Pain Market Size and Volume Forecast by Applications
     11.4.1. Sinusitis
     11.4.2. Migraines
     11.4.3. Glaucoma
     11.4.4. Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Asia Pacific Chronic Ocular Surface Pain Market Size and Volume Forecast by End Users
     11.7.1. Hospitals
     11.7.2. Homecare
     11.7.3. Specialty Clinics
     11.7.4. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Chronic Ocular Surface Pain Demand Share Forecast, 2019-2026
12. Middle East & Africa Chronic Ocular Surface Pain Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Chronic Ocular Surface Pain Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Chronic Ocular Surface Pain Market Size and Volume Forecast by Applications
     12.4.1. Sinusitis
     12.4.2. Migraines
     12.4.3. Glaucoma
     12.4.4. Others
  12.5. Basis Point Share (BPS) Analysis by Applications
  12.6. Y-o-Y Growth Projections by Applications
  12.7. Middle East & Africa Chronic Ocular Surface Pain Market Size and Volume Forecast by End Users
     12.7.1. Hospitals
     12.7.2. Homecare
     12.7.3. Specialty Clinics
     12.7.4. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Chronic Ocular Surface Pain Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Chronic Ocular Surface Pain Market: Market Share Analysis
  13.2. Chronic Ocular Surface Pain Distributors and Customers
  13.3. Chronic Ocular Surface Pain Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. AstraZeneca
     13.4.2. F. Hoffmann-La Roche Ltd
     13.4.3. GSK plc
     13.4.4. Johnson & Johnson Services, Inc
     13.4.5. Merck KGaA
     13.4.6. Novartis AG
     13.4.7. OKYO Pharma
     13.4.8. Pfizer Inc
     13.4.9. Sanofi
     13.4.10. Sun Pharmaceutical Industries Ltd
     13.4.11. Viatris Inc

Methodology

Our Clients

Microsoft
sinopec
Nestle SA
The John Holland Group
Pfizer
General Mills
Dassault Aviation
General Electric